CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
Status:
Recruiting
Trial end date:
2023-09-18
Target enrollment:
Participant gender:
Summary
This phase I trial investigates the side effects of chemotherapy and cellular immunotherapy
in treating children with IL13Ralpha2 positive brain tumors that have come back after a
period of improvement (recurrent) or do not respond to treatment (refractory). Cellular
immunotherapy (IL13(EQ)BBzeta/CD19t+ T cells) are brain-tumor specific cells that may induce
changes in body's immune system and may interfere with the ability of tumor cells to grow and
spread. Chemotherapy drugs, such as as cyclophosphamide and fludarabine, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Many patients with brain tumor respond to
treatment, but then the tumor starts to grow again. Giving chemotherapy in combination with
cellular immunotherapy may kill more tumor cells and improve the outcome of treatment.